433 related articles for article (PubMed ID: 26381393)
1. Pilot Study of Natural Killer Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis.
Huth TK; Brenu EW; Ramos S; Nguyen T; Broadley S; Staines D; Marshall-Gradisnik S
Scand J Immunol; 2016 Jan; 83(1):44-51. PubMed ID: 26381393
[TBL] [Abstract][Full Text] [Related]
2. ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56 dim CD16+ and CD56 bright CD16 dim/- natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients.
Huth TK; Staines D; Marshall-Gradisnik S
J Transl Med; 2016 Apr; 14():97. PubMed ID: 27098723
[TBL] [Abstract][Full Text] [Related]
3. Characterisation of cell functions and receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME).
Hardcastle SL; Brenu EW; Johnston S; Nguyen T; Huth T; Wong N; Ramos S; Staines D; Marshall-Gradisnik S
BMC Immunol; 2015 Jun; 16():35. PubMed ID: 26032326
[TBL] [Abstract][Full Text] [Related]
4. Impaired calcium mobilization in natural killer cells from chronic fatigue syndrome/myalgic encephalomyelitis patients is associated with transient receptor potential melastatin 3 ion channels.
Nguyen T; Johnston S; Clarke L; Smith P; Staines D; Marshall-Gradisnik S
Clin Exp Immunol; 2017 Feb; 187(2):284-293. PubMed ID: 27727448
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal analysis of immune abnormalities in varying severities of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients.
Hardcastle SL; Brenu EW; Johnston S; Nguyen T; Huth T; Ramos S; Staines D; Marshall-Gradisnik S
J Transl Med; 2015 Sep; 13():299. PubMed ID: 26370228
[TBL] [Abstract][Full Text] [Related]
6. Transient receptor potential melastatin 2 channels are overexpressed in myalgic encephalomyelitis/chronic fatigue syndrome patients.
Balinas C; Cabanas H; Staines D; Marshall-Gradisnik S
J Transl Med; 2019 Dec; 17(1):401. PubMed ID: 31796045
[TBL] [Abstract][Full Text] [Related]
7. Regulatory T, natural killer T and γδ T cells in multiple sclerosis and chronic fatigue syndrome/myalgic encephalomyelitis: a comparison.
Ramos S; Brenu E; Broadley S; Kwiatek R; Ng J; Nguyen T; Freeman S; Staines D; Marshall-Gradisnik S
Asian Pac J Allergy Immunol; 2016 Dec; 34(4):300-305. PubMed ID: 27001659
[TBL] [Abstract][Full Text] [Related]
8. Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation.
Eaton N; Cabanas H; Balinas C; Klein A; Staines D; Marshall-Gradisnik S
BMC Pharmacol Toxicol; 2018 Mar; 19(1):12. PubMed ID: 29587879
[TBL] [Abstract][Full Text] [Related]
9. Role of adaptive and innate immune cells in chronic fatigue syndrome/myalgic encephalomyelitis.
Brenu EW; Huth TK; Hardcastle SL; Fuller K; Kaur M; Johnston S; Ramos SB; Staines DR; Marshall-Gradisnik SM
Int Immunol; 2014 Apr; 26(4):233-42. PubMed ID: 24343819
[TBL] [Abstract][Full Text] [Related]
10. Novel identification and characterisation of Transient receptor potential melastatin 3 ion channels on Natural Killer cells and B lymphocytes: effects on cell signalling in Chronic fatigue syndrome/Myalgic encephalomyelitis patients.
Nguyen T; Staines D; Nilius B; Smith P; Marshall-Gradisnik S
Biol Res; 2016 May; 49(1):27. PubMed ID: 27245705
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal investigation of natural killer cells and cytokines in chronic fatigue syndrome/myalgic encephalomyelitis.
Brenu EW; van Driel ML; Staines DR; Ashton KJ; Hardcastle SL; Keane J; Tajouri L; Peterson D; Ramos SB; Marshall-Gradisnik SM
J Transl Med; 2012 May; 10():88. PubMed ID: 22571715
[TBL] [Abstract][Full Text] [Related]
12. Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis.
Brenu EW; van Driel ML; Staines DR; Ashton KJ; Ramos SB; Keane J; Klimas NG; Marshall-Gradisnik SM
J Transl Med; 2011 May; 9():81. PubMed ID: 21619669
[TBL] [Abstract][Full Text] [Related]
13. Association of T and NK Cell Phenotype With the Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
Rivas JL; Palencia T; Fernández G; García M
Front Immunol; 2018; 9():1028. PubMed ID: 29867995
[TBL] [Abstract][Full Text] [Related]
14. Loss of Transient Receptor Potential Melastatin 3 ion channel function in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients.
Cabanas H; Muraki K; Eaton N; Balinas C; Staines D; Marshall-Gradisnik S
Mol Med; 2018 Aug; 24(1):44. PubMed ID: 30134818
[TBL] [Abstract][Full Text] [Related]
15. Immune and hemorheological changes in chronic fatigue syndrome.
Brenu EW; Staines DR; Baskurt OK; Ashton KJ; Ramos SB; Christy RM; Marshall-Gradisnik SM
J Transl Med; 2010 Jan; 8():1. PubMed ID: 20064266
[TBL] [Abstract][Full Text] [Related]
16. Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis patients.
Cabanas H; Muraki K; Balinas C; Eaton-Fitch N; Staines D; Marshall-Gradisnik S
Mol Med; 2019 Apr; 25(1):14. PubMed ID: 31014226
[TBL] [Abstract][Full Text] [Related]
17. Cellular Immune Function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
Cliff JM; King EC; Lee JS; Sepúlveda N; Wolf AS; Kingdon C; Bowman E; Dockrell HM; Nacul L; Lacerda E; Riley EM
Front Immunol; 2019; 10():796. PubMed ID: 31057538
[TBL] [Abstract][Full Text] [Related]
18. Impact of Long-Term Cryopreservation on Blood Immune Cell Markers in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Implications for Biomarker Discovery.
Gómez-Mora E; Carrillo J; Urrea V; Rigau J; Alegre J; Cabrera C; Oltra E; Castro-Marrero J; Blanco J
Front Immunol; 2020; 11():582330. PubMed ID: 33329554
[TBL] [Abstract][Full Text] [Related]
19. Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment.
Cabanas H; Muraki K; Eaton-Fitch N; Staines DR; Marshall-Gradisnik S
Front Immunol; 2021; 12():687806. PubMed ID: 34326841
[TBL] [Abstract][Full Text] [Related]
20. Terminal Differentiation of CD56(dim)CD16(+) Natural Killer Cells Is Associated with Increase in Natural Killer Cell Frequencies After Antiretroviral Treatment in HIV-1 Infection.
Ahmad F; Tufa DM; Mishra N; Jacobs R; Schmidt RE
AIDS Res Hum Retroviruses; 2015 Dec; 31(12):1206-12. PubMed ID: 26352913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
